Your browser doesn't support javascript.
loading
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-ß receptor type I inhibitor.
Yingling, Jonathan M; McMillen, William T; Yan, Lei; Huang, Huocong; Sawyer, J Scott; Graff, Jeremy; Clawson, David K; Britt, Karen S; Anderson, Bryan D; Beight, Douglas W; Desaiah, Durisala; Lahn, Michael M; Benhadji, Karim A; Lallena, Maria J; Holmgaard, Rikke B; Xu, Xiaohong; Zhang, Faming; Manro, Jason R; Iversen, Philip W; Iyer, Chandrasekar V; Brekken, Rolf A; Kalos, Michael D; Driscoll, Kyla E.
Affiliation
  • Yingling JM; Idera Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • McMillen WT; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Yan L; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Huang H; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Sawyer JS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Graff J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Clawson DK; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Britt KS; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Anderson BD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Beight DW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Desaiah D; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Lahn MM; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Benhadji KA; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Lallena MJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Holmgaard RB; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Xu X; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Zhang F; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Iversen PW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Iyer CV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Brekken RA; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Kalos MD; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
  • Driscoll KE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN and New York, NY, USA.
Oncotarget ; 9(6): 6659-6677, 2018 Jan 23.
Article in En | MEDLINE | ID: mdl-29467918
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article